Oxycodone-naltrexone: Clinical trial data

Pfizer reported data from 2 abuse potential studies with ALO-02 at the American Pain Society meeting in Tampa. A double-blind, placebo- and active-controlled, 6-way crossover abuse potential trial in 41 healthy, non-dependent recreational opioid users showed that oral administration of 40 mg crushed ALO-02 and 60 mg of crushed and intact ALO-02 resulted in significantly lower “drug liking and high” scores vs. equivalent doses of crushed immediate-release (IR) oxycodone. A double-blind, placebo- and active-controlled, 4-way crossover abuse potential trial in 32 healthy, non-dependent recreational opioid users showed that intranasal administration of 30 mg crushed ALO-02 resulted in significantly lower “drug liking and high” scores vs. 30 mg crushed IR oxycodone. ...